Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

Bristol-Myers Squibb Company (BMY) EV/Assets Ratio: 1.72x

Is Bristol-Myers Squibb Company’s EV/Assets ratio high or low?

Bristol-Myers Squibb Company's EV/Assets ratio of 1.72x is in line with its 5-year average of 1.64x, around the middle of its 5-year range (1.30x–2.10x).

The EV/Assets ratio for Bristol-Myers Squibb Company (BMY) is 1.72x as of Wednesday, June 10, 2026. It is above its 12-month average by 11.33% (1.55x).

BMY EV/Assets Ratio Chart

BMY EV/Assets Ratio
1.72x+11.69% 1Y
Zoom

BMY Average EV/Assets Ratio Chart

BMY Current vs Average EV/Assets Ratio Chart

BMY EV/Assets Ratio Metrics

EV/ASSETS RATIO

1.72x

EV/ASSETS RATIO AVG TTM

1.55x

EV/ASSETS RATIO AVG 3Y

1.56x

EV/ASSETS RATIO AVG 5Y

1.64x

EV/ASSETS RATIO AVG 10Y

1.98x

EV/ASSETS RATIO AVG 15Y

2.16x

EV/ASSETS RATIO AVG 20Y

2.05x

CURRENT VS TTM AVG

+11.33%

CURRENT VS 3Y AVG

+10.33%

CURRENT VS 5Y AVG

+4.57%

CURRENT VS 10Y AVG

-13.29%

CURRENT VS 15Y AVG

-20.19%

CURRENT VS 20Y AVG

-16.28%

BMY Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
Bristol-Myers Squibb Company (BMY)$114.14B1.72x1.55x1.56x1.64x
Vertex Pharmaceuticals Incorporated (VRTX)$110.77B4.10x4.45x4.69x4.46x
CVS Health Corporation (CVS)$125.16B0.77x0.67x0.63x0.70x
Medtronic plc (MDT)$103.04B1.42x1.59x1.53x1.60x
Danaher Corporation (DHR)$130.25B1.72x1.98x2.16x2.26x
Elevance Health Inc. (ELV)$87.43B0.88x0.80x1.03x1.13x
Pfizer Inc. (PFE)$146.36B1.01x1.00x1.03x1.28x
Intuitive Surgical, Inc. (ISRG)$146.44B7.30x8.88x9.09x8.50x
Cigna Corporation (CI)$78.25B0.67x0.66x0.72x0.73x
Gilead Sciences, Inc. (GILD)$151.21B2.97x3.05x2.44x2.15x

Bristol-Myers Squibb Company EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bristol-Myers Squibb Company EV/Assets Ratio FAQ

What is the EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
The EV/Assets ratio for BMY stock is 1.72x.
Is Bristol-Myers Squibb Company's EV/Assets ratio high or low?
Bristol-Myers Squibb Company's EV/Assets ratio of 1.72x is in line with its 5-year average of 1.64x, around the middle of its 5-year range (1.30x–2.10x).
What is the TTM average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
The TTM average EV/Assets ratio for BMY stock is 1.55x.
What is the 3Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
The 3Y average EV/Assets ratio for BMY stock is 1.56x.
What is the 5Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
The 5Y average EV/Assets ratio for BMY stock is 1.64x.
What is the 10Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
The 10Y average EV/Assets ratio for BMY stock is 1.98x.
What is the 15Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
The 15Y average EV/Assets ratio for BMY stock is 2.16x.
What is the 20Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
The 20Y average EV/Assets ratio for BMY stock is 2.05x.

Bristol-Myers Squibb Company EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-101.72x
2026-06-091.74x
2026-06-081.72x
2026-06-051.76x
2026-06-041.74x
2026-06-031.70x
2026-06-021.69x
2026-06-011.70x
2026-05-291.75x
2026-05-281.75x
2026-05-271.76x
2026-05-261.77x
2026-05-221.81x
2026-05-211.81x
2026-05-201.79x
2026-05-191.78x
2026-05-181.76x
2026-05-151.75x
2026-05-141.74x
2026-05-131.74x
2026-05-121.74x
2026-05-111.72x
2026-05-081.73x
2026-05-071.73x
2026-05-061.74x
2026-05-051.75x
2026-05-041.76x
2026-05-011.78x
2026-04-301.84x
2026-04-291.72x
2026-04-281.73x
2026-04-271.72x
2026-04-241.74x
2026-04-231.75x
2026-04-221.74x
2026-04-211.76x
2026-04-201.75x
2026-04-171.77x
2026-04-161.75x
2026-04-151.72x
2026-04-141.73x
2026-04-131.73x
2026-04-101.74x
2026-04-091.76x
2026-04-081.75x
2026-04-071.72x
2026-04-061.76x
2026-04-021.76x
2026-04-011.81x
2026-03-311.78x
2026-03-301.76x
2026-03-271.74x
2026-03-261.76x
2026-03-251.75x
2026-03-241.71x
2026-03-231.70x
2026-03-201.71x
2026-03-191.73x
2026-03-181.76x
2026-03-171.76x
2026-03-161.76x
2026-03-131.75x
2026-03-121.75x
2026-03-111.77x
2026-03-101.77x
2026-03-091.78x
2026-03-061.78x
2026-03-051.79x
2026-03-041.82x
2026-03-031.80x
2026-03-021.82x
2026-02-271.82x
2026-02-261.80x
2026-02-251.80x
2026-02-241.81x
2026-02-231.80x
2026-02-201.79x
2026-02-191.78x
2026-02-181.76x
2026-02-171.78x
2026-02-131.79x
2026-02-121.77x
2026-02-111.77x
2026-02-101.64x
2026-02-091.64x
2026-02-061.67x
2026-02-051.62x
2026-02-041.58x
2026-02-031.54x
2026-02-021.54x
2026-01-301.52x
2026-01-291.51x
2026-01-281.51x
2026-01-271.53x
2026-01-261.51x
2026-01-231.51x
2026-01-221.52x
2026-01-211.51x
2026-01-201.50x
2026-01-161.53x
2026-01-151.56x
2026-01-141.56x
2026-01-131.54x
2026-01-121.54x
2026-01-091.54x
2026-01-081.54x
2026-01-071.56x
2026-01-061.51x
2026-01-051.48x
2026-01-021.49x
2025-12-311.50x
2025-12-301.50x
2025-12-291.50x
2025-12-261.51x
2025-12-241.52x
2025-12-231.51x
2025-12-221.51x
2025-12-191.50x
2025-12-181.49x
2025-12-171.49x
2025-12-161.51x
2025-12-151.51x
2025-12-121.47x
2025-12-111.44x
2025-12-101.44x
2025-12-091.43x
2025-12-081.45x
2025-12-051.46x
2025-12-041.46x
2025-12-031.44x
2025-12-021.38x
2025-12-011.40x
2025-11-281.40x
2025-11-261.40x
2025-11-251.40x
2025-11-241.37x
2025-11-211.34x
2025-11-201.33x
2025-11-191.33x
2025-11-181.35x
2025-11-171.35x
2025-11-141.35x
2025-11-131.39x
2025-11-121.40x
2025-11-111.39x
2025-11-101.36x
2025-11-071.35x
2025-11-061.35x
2025-11-051.34x
2025-11-041.32x
2025-11-031.33x
2025-10-311.33x
2025-10-301.32x
2025-10-291.32x
2025-10-281.33x
2025-10-271.34x
2025-10-241.35x
2025-10-231.35x
2025-10-221.36x
2025-10-211.36x
2025-10-201.34x
2025-10-171.34x
2025-10-161.34x
2025-10-151.34x
2025-10-141.35x
2025-10-131.34x
2025-10-101.35x
2025-10-091.37x
2025-10-081.36x
2025-10-071.37x
2025-10-061.38x
2025-10-031.38x
2025-10-021.39x
2025-10-011.43x
2025-09-301.38x
2025-09-291.36x
2025-09-261.35x
2025-09-251.34x
2025-09-241.36x
2025-09-231.37x
2025-09-221.37x
2025-09-191.37x
2025-09-181.39x
2025-09-171.40x
2025-09-161.40x
2025-09-151.40x
2025-09-121.40x
2025-09-111.43x
2025-09-101.42x
2025-09-091.42x
2025-09-081.41x
2025-09-051.42x
2025-09-041.41x
2025-09-031.43x
2025-09-021.43x
2025-08-291.42x
2025-08-281.41x
2025-08-271.43x
2025-08-261.42x
2025-08-251.42x
2025-08-221.44x
2025-08-211.45x
2025-08-201.44x
2025-08-191.45x
2025-08-181.44x
2025-08-151.45x
2025-08-141.43x
2025-08-131.43x
2025-08-121.41x
2025-08-111.39x
2025-08-081.39x
2025-08-071.38x
2025-08-061.37x
2025-08-051.39x
2025-08-041.38x
2025-08-011.36x
2025-07-311.34x
2025-07-301.45x
2025-07-291.47x
2025-07-281.48x
2025-07-251.50x
2025-07-241.52x
2025-07-231.52x
2025-07-221.50x
2025-07-211.47x
2025-07-181.48x
2025-07-171.50x
2025-07-161.48x
2025-07-151.46x
2025-07-141.48x
2025-07-111.47x
2025-07-101.51x
2025-07-091.49x
2025-07-081.47x
2025-07-071.46x
2025-07-031.47x
2025-07-021.49x
2025-07-011.48x
2025-06-301.46x
2025-06-271.46x
2025-06-261.46x
2025-06-251.47x
2025-06-241.47x
2025-06-231.47x
2025-06-201.47x
2025-06-181.47x
2025-06-171.48x
2025-06-161.51x
2025-06-131.53x
2025-06-121.55x
2025-06-111.54x
2025-06-101.54x
2025-06-091.52x
2025-06-061.50x
2025-06-051.49x
2025-06-041.49x
2025-06-031.50x
2025-06-021.51x
2025-05-301.50x
2025-05-291.49x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner